FIELD: pharmacology.
SUBSTANCE: invention relates to compounds of the Formula (I) or their pharmaceutically acceptable salts inhibiting the activity of cystathionine-gamma-lyase (CSE). In Formula (I) A is
or -CONHSO2R4, where R4 is independently unsubstituted alkyl or unsubstituted aryl; X is CR1 or N; R1 is H; each R2 and R3 is H. The invention also relates to a pharmaceutical composition comprising the said compounds and a method for treatment or prevention of various diseases associated with CSE activity.
EFFECT: increased efficiency of the composition and treatment method.
13 cl, 11 dwg, 2 tbl, 17 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CYSTATHIONINE-γ-LYASE (CSE) INHIBITORS | 2013 |
|
RU2661879C2 |
| SUBSTITUTED TRIAZOLES AS SODIUM CHANNEL BLOCKERS | 2004 |
|
RU2372339C2 |
| COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | 2007 |
|
RU2470012C2 |
| 3,4-DIHYDROBENZOXAZINE COMPOUNDS AND VANILLOID RECEPTOR SUBTYPE 1 (VR1) INHIBITORS | 2006 |
|
RU2427579C2 |
| SIGMA-LIGANDS FOR APPLICATION IN PREVENTION AND/OR TREATMENT OF POSTOPERATIVE PAIN | 2011 |
|
RU2569055C2 |
| 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS | 2009 |
|
RU2515612C2 |
| PROTEIN TYROSINE KINASE RECEPTOR INHIBITOR COMPOSITIONS | 2009 |
|
RU2586212C2 |
| PERIPHERALLY RESTRICTED FAAH INHIBITORS | 2011 |
|
RU2583435C2 |
| ANALGETIC COMPOUND AND ITS PRODUCTION METHOD | 2018 |
|
RU2791108C2 |
| PHARMACEUTICAL COMPOSITIONS OF SPIRO-OXINDOLE COMPOUND FOR LOCAL ADMINISTRATION AND USE THEREOF AS THERAPEUTIC AGENTS | 2011 |
|
RU2596488C2 |
